Erratum: Stat3 inhibitor stattic exhibits potent antitumor activity and induces chemoand radio-sensitivity in nasopharyngeal carcinoma (PLoS ONE (2013) 8:1 (e54565) DOI: 10.1371/journal.pone.0054565);Stat3 Inhibitor Stattic Exhibits Potent Antitumor Activity and Induces Chemo- and Radio-Sensitivity in Nasopharyngeal Carcinoma

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Pan, Yunbao ^a,b   Zhou, Fuling ^a,c   Zhang, Ronghua ^a   Claret, Francois X ^a,d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b SUN YAT SEN UNIVERSITY   (China)

^c XI'AN JIAOTONG UNIVERSITY   (China)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLIN D1; INTERLEUKIN 6; STAT3 PROTEIN; STATTIC; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CANCER RESISTANCE; CELL ASSAY; CELL CYCLE ARREST; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; INTRACELLULAR SIGNALING; IONIZING RADIATION; NASOPHARYNX CARCINOMA; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TARGETING; RADIOSENSITIVITY;

EID: 84873857266     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0237943     Document Type: Erratum

References (41)

1. Wei WI, Sham JS, (2005) Nasopharyngeal carcinoma. Lancet 365: 2041-2054.
2. Lo KW, Chung GT, To KF, (2012) Deciphering the molecular genetic basis of NPC through molecular, cytogenetic, and epigenetic approaches. Seminars in cancer biology 22: 79-86.
3. Spano JP, Busson P, Atlan D, Bourhis J, Pignon JP, et al. (2003) Nasopharyngeal carcinomas: an update. European journal of cancer 39: 2121-2135.
4. Lo KW, To KF, Huang DP, (2004) Focus on nasopharyngeal carcinoma. Cancer cell 5: 423-428.
5. Hui EP, Ma BB, Leung SF, King AD, Mo F, et al. (2009) Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. Journal of clinical oncology 27: 242-249.
6. Chan AT, (2010) Nasopharyngeal carcinoma. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 21Suppl 7: vii308-312.
7. Yip KW, Mocanu JD, Au PY, Sleep GT, Huang D, et al. (2005) Combination bcl-2 antisense and radiation therapy for nasopharyngeal cancer. Clinical cancer research 11: 8131-8144.
8. Pan Y, Zhang Q, Tian L, Wang X, Fan X, et al. (2012) Jab1/CSN5 negatively regulates p27 and plays a role in the pathogenesis of nasopharyngeal carcinoma. Cancer research 72: 1890-1900.
9. Pan Y, Zhang Q, Atsaves V, Yang H, Claret FX (2012) Suppression of Jab1/CSN5 induces radio- and chemo-sensitivity in nasopharyngeal carcinoma through changes to the DNA damage and repair pathways. Oncogene: doi:10.1038/onc.2012.1294.
10. Pan Y, Claret FX, (2012) Targeting Jab1/CSN5 in nasopharyngeal carcinoma. Cancer letters 326: 155-160.
11. Zhong Z, Wen Z, Darnell JE Jr, (1994) Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264: 95-98.
12. Sasse J, Hemmann U, Schwartz C, Schniertshauer U, Heesel B, et al. (1997) Mutational analysis of acute-phase response factor/Stat3 activation and dimerization. Molecular and cellular biology 17: 4677-4686.
13. Yu H, Jove R, (2004) The STATs of cancer-new molecular targets come of age. Nature reviews Cancer 4: 97-105.
14. Buettner R, Mora LB, Jove R, (2002) Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clinical cancer research 8: 945-954.
15. Real PJ, Sierra A, De Juan A, Segovia JC, Lopez-Vega JM, et al. (2002) Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene 21: 7611-7618.
16. Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, et al. (2004) Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nature medicine 10: 48-54.
17. Lui VW, Wong EY, Ho Y, Hong B, Wong SC, et al. (2009) STAT3 activation contributes directly to Epstein-Barr virus-mediated invasiveness of nasopharyngeal cancer cells in vitro. International journal of cancer 125: 1884-1893.
18. Chen H, Hutt-Fletcher L, Cao L, Hayward SD, (2003) A positive autoregulatory loop of LMP1 expression and STAT activation in epithelial cells latently infected with Epstein-Barr virus. Journal of virology 77: 4139-4148.
19. Wang Z, Luo F, Li L, Yang L, Hu D, et al. (2010) STAT3 activation induced by Epstein-Barr virus latent membrane protein1 causes vascular endothelial growth factor expression and cellular invasiveness via JAK3 And ERK signaling. European journal of cancer 46: 2996-3006.
20. Akira S, (2000) Roles of STAT3 defined by tissue-specific gene targeting. Oncogene 19: 2607-2611.
21. Lai SY, Johnson FM, (2010) Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches. Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy 13: 67-78.
22. Song H, Wang R, Wang S, Lin J, (2005) A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America 102: 4700-4705.
23. Becker S, Groner B, Muller CW, (1998) Three-dimensional structure of the Stat3beta homodimer bound to DNA. Nature 394: 145-151.
24. Schust J, Sperl B, Hollis A, Mayer TU, Berg T, (2006) Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chemistry & biology 13: 1235-1242.
25. Lin L, Liu A, Peng Z, Lin HJ, Li PK, et al. (2011) STAT3 is necessary for proliferation and survival in colon cancer-initiating cells. Cancer research 71: 7226-7237.
26. Shackleford TJ, Zhang Q, Tian L, Vu TT, Korapati AL, et al. (2011) Stat3 and CCAAT/enhancer binding protein beta (C/EBP-beta) regulate Jab1/CSN5 expression in mammary carcinoma cells. Breast cancer research 13: R65.
27. Tu B, Du L, Fan QM, Tang Z, Tang TT (2012) STAT3 activation by IL-6 from mesenchymal stem cells promotes the proliferation and metastasis of osteosarcoma. Cancer letters.
28. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC, (1994) Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 371: 346-347.
29. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, et al. (1995) Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376: 37-43.
30. Hsiao JR, Jin YT, Tsai ST, Shiau AL, Wu CL, et al. (2003) Constitutive activation of STAT3 and STAT5 is present in the majority of nasopharyngeal carcinoma and correlates with better prognosis. British journal of cancer 89: 344-349.
31. Wang X, Crowe PJ, Goldstein D, Yang JL (2012) STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers (Review). International journal of oncology: doi:10.3892/ijo.2012.1568.
32. Shanmugam MK, Nguyen AH, Kumar AP, Tan BK, Sethi G, (2012) Targeted inhibition of tumor proliferation, survival, and metastasis by pentacyclic triterpenoids: potential role in prevention and therapy of cancer. Cancer letters 320: 158-170.
33. Yue P, Turkson J, (2009) Targeting STAT3 in cancer: how successful are we? Expert opinion on investigational drugs 18: 45-56.
34. Frank DA, (2007) STAT3 as a central mediator of neoplastic cellular transformation. Cancer letters 251: 199-210.
35. Adachi M, Cui C, Dodge CT, Bhayani MK, Lai SY (2012) Targeting STAT3 inhibits growth and enhances radiosensitivity in head and neck squamous cell carcinoma. Oral oncology.
36. Yue P, Zhang X, Paladino D, Sengupta B, Ahmad S, et al. (2012) Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells. Oncogene 31: 2309-2322.
37. Huang S, Chen M, Shen Y, Shen W, Guo H, et al. (2012) Inhibition of activated Stat3 reverses drug resistance to chemotherapeutic agents in gastric cancer cells. Cancer letters 315: 198-205.
38. Bonner JA, Trummell HQ, Willey CD, Plants BA, Raisch KP, (2009) Inhibition of STAT-3 results in radiosensitization of human squamous cell carcinoma. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology 92: 339-344.
39. Xu X, Kasembeli MM, Jiang X, Tweardy BJ, Tweardy DJ, (2009) Chemical probes that competitively and selectively inhibit Stat3 activation. PloS one 4: e4783.
40. Redell MS, Ruiz MJ, Alonzo TA, Gerbing RB, Tweardy DJ, (2011) Stat3 signaling in acute myeloid leukemia: ligand-dependent and-independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood 117: 5701-5709.
41. Siddiquee K, Zhang S, Guida WC, Blaskovich MA, Greedy B, et al. (2007) Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proceedings of the National Academy of Sciences of the United States of America 104: 7391-7396.